Resverlogix Receives Ethics Approval for Canadian Sites in Apabetalone COVID-19 Clinical Trial
October 12, 2021 16:35 ET | Resverlogix Corp
CALGARY, Alberta, Oct. 12, 2021 (GLOBE NEWSWIRE) -- Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX), today announces the approval of its COVID-19 clinical trial of apabetalone by the...
Study Demonstrates Resverlogix’s Apabetalone Treatment Significantly Improves Cognition and Reduces Cognitive Decline Among Patients with Both Cardiovascular Disease and Diabetes Mellitus
September 13, 2021 08:00 ET | Resverlogix Corp
Positive Findings in Journal of Alzheimer's Disease Suggest BET Inhibitor Apabetalone Holds Promise as a Safe and Effective Therapeutic for Vascular Cognitive Impairment Apabetalone is a...